
Opinion|Videos|January 29, 2025
Final Insights
Key Takeaways
- Pediatric lipid screening is vital for early dyslipidemia detection, reducing future cardiovascular disease risk.
- Guidelines suggest universal screening at ages 9-11 and 17-21, with selective screening for at-risk children.
Panelists discuss how effective cardiovascular risk management requires comprehensive screening for both LDL-C and Lp(a), along with aggressive treatment strategies for high-risk patients.
Advertisement
Episodes in this series

Video content above is prompted by the following:
Are there any final insights you’d like to share regarding LDL-C and Lp(a) screening and management of high-risk cardiovascular patients?
Advertisement
Latest CME
Advertisement
Advertisement
Trending on HCPLive
1
OMA 2026 Recap: Pediatrics, Retention, and Lifestyle Changes in Obesity
2
A Real-World Case: Initiating Ritlecitinib After Years of Untreated Disease
3
Choosing Among Approved JAK Inhibitors: Baricitinib, Ritlecitinib, and Deuruxolitinib
4
CX11 Shows Weight Loss in Phase 2 Obesity Trial, Corxel Reports
5





































































